Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of Revance's common stock for $6.66 per share in cash. This transaction signifies a total enterprise value of $924 million and represents an 89% premium relative to Revance's closing price on August 9, 2024.

Revance Therapeutics，Inc.（RVNC）周一透露，它已与Crown Laboratories，Inc.签署了一份合并协议，Crown Laboratories，Inc.计划以每股6.66美元的现金购买Revance普通股的所有流通股。该交易意味着企业总价值为9.24亿美元，相对于Revance 2024年8月9日的收盘价，溢价为89%。

Following the news, the stock rose 85% in pre-market.The objective of the merger is to establish a prominent and innovative company in the aesthetics and skincare sector, integrating Crown's skincare products with Revance's aesthetic solutions. Upon the successful completion of the merger, Revance will become a wholly owned subsidiary of Crown, and its stock will cease to be publicly traded on Nasdaq..

消息传出后，该股在上市前上涨了85%。合并的目标是在美学和护肤领域建立一家卓越而创新的公司，将皇冠的护肤产品与Revance的美学解决方案相结合。合并成功后，Revance将成为Crown的全资子公司，其股票将停止在纳斯达克上市交易。。

The transaction is anticipated to be finalized by the end of the year, pending stockholder approval and necessary regulatory clearances.In pre-market activity on the Nasdaq, the shares are trading at $6.58, up 85.40%. For comments and feedback contact: editorial@rttnews.comBusiness News

预计该交易将于年底完成，等待股东批准和必要的监管许可。在纳斯达克（Nasdaq）的上市前活动中，该公司股价为6.58美元，上涨85.40%。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股